We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Impact of S‐1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real‐world data.
- Authors
Tomimaru, Yoshito; Eguchi, Hidetoshi; Inoue, Yosuke; Nagakawa, Yuichi; Ohba, Akihiro; Takami, Hideki; Unno, Michiaki; Yamamoto, Tomohisa; Kawakatsu, Shoji; Hayashi, Tsuyoshi; Higuchi, Ryota; Kitagawa, Hirohisa; Hattori, Satoshi; Fujii, Tsutomu; Hirooka, Yoshiki; Igarashi, Hisato; Kitano, Masayuki; Kuroki, Tamotsu; Masamune, Atsushi; Shimizu, Yasuhiro
- Abstract
Background: Based on the Japan Adjuvant Study Group of Pancreatic Cancer 01 study, the standard duration of adjuvant chemotherapy with S‐1 (an oral 5‐fluorouracil prodrug consisting of tegafur, gimeracil, and oteracil) in patients with resected pancreatic ductal adenocarcinoma (PDAC) was considered to be 6 months, but the impact of increasing its duration on postoperative survival was unknown. Here, the authors investigated this question by reviewing real‐world data from a large cohort of patients with PDAC. Methods: In total, 3949 patients who underwent surgery for PDAC during the study period followed by S‐1 adjuvant chemotherapy in board‐certified institutions were included. Based on the duration of S‐1 chemotherapy, two subgroups were defined: a standard‐duration group that included patients who were treated for 180 ± 30 days and a longer duration group that included patients who received treatment for >210 days. Results: The median duration of S‐1 chemotherapy was 167 days, with a mean ± standard deviation of 200 ± 193 days. After excluding patients who had a recurrence within 210 days after the initiation of adjuvant chemotherapy, postoperative recurrence‐free survival (RFS) and overall survival (OS) in the standard‐duration group (n = 1473) and the longer duration group (n = 975) were compared. RFS and OS did not differ significantly between the standard‐duration and longer duration groups (5‐year RFS: 37.8% vs. 36.2% respectively; p =.6186; 5‐year OS: 52.8% vs. 53.4%, respectively; p =.5850). The insignificant difference was verified by multivariate analysis and propensity‐score matching analysis. Conclusions: The current findings suggest that extending S‐1 adjuvant chemotherapy beyond 6 months has no significant additional effect on survival in patients with PDAC. This could be useful in determining whether to extend S‐1 chemotherapy in patients who have completed the standard 6‐month treatment. The impact of S‐1 adjuvant chemotherapy for a longer period than the standard duration (6 months) on postoperative survival was investigated in patients who had resected pancreatic ductal adenocarcinoma based on a nationwide survey that collected real‐world data. The results demonstrated that the extension of S‐1 adjuvant chemotherapy beyond 6 months had no significant additional effect on survival.
- Subjects
ADJUVANT chemotherapy; PANCREATIC cancer; OVERALL survival; PANCREATIC duct; PANCREAS
- Publication
Cancer (0008543X), 2023, Vol 129, Issue 5, p728
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.34580